AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Kiniksa Pharmaceuticals International, plc

$76.27 +$34.26 (+81.55%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$76.48
Day Range
$76.14$78.59
Year Range
$35.2$82.94
Market Cap
5.81B
AVG Volume
675.88K
Trailing/Forward PE
71.28/37.18
PEG ratio
1.51
Dividend Yield
-
Next Earnings Date
2026-10-27
Primary Exchange
NASDAQUS
Revenue (USD)
0200M400M600M800M201720182019202020212022202320242025
KNSA Revenue (USD) by year
PeriodRevenue (USD)
2025677.56M
2024423.24M
2023270.26M
2022220.18M
202138.54M
20200
20190
20180
20170
Net Income (USD)
-200M-100M0100M200M201720182019202020212022202320242025
KNSA Net Income (USD) by year
PeriodNet Income (USD)
202559.01M
2024-43.19M
202314.08M
2022183.36M
2021-157.92M
2020-161.38M
2019-161.87M
2018-103.23M
2017-64.87M
Operating Income (USD)
-200M-100M0100M201720182019202020212022202320242025
KNSA Operating Income (USD) by year
PeriodOperating Income (USD)
202577.22M
2024-45.62M
2023-25.2M
20229.77M
2021-156.64M
2020-157.36M
2019-169.96M
2018-108.16M
2017-65.4M
EBITDA (USD)
-200M-100M0100M201720182019202020212022202320242025
KNSA EBITDA (USD) by year
PeriodEBITDA (USD)
202590.42M
2024-34.46M
2023-13.23M
202215.25M
2021-152.9M
2020-154.96M
2019-167.9M
2018-107.88M
2017-65.37M
Cash Flows (USD)
-200M-100M0100M200M201720182019202020212022202320242025
KNSA Cash Flows (USD) by year
PeriodCash Flows (USD)
2025136.42M
202425.41M
202313.17M
20225.7M
2021-146.71M
2020-136.81M
2019-161.57M
2018-86.3M
2017-50.29M
EPS (USD)
-4-2024201720182019202020212022202320242025
KNSA EPS (USD) by year
PeriodEPS (USD)
20250.75
2024-0.6
20230.18
20222.59
2021-2.3
2020-2.58
2019-3.02
2018-2.84
2017-2
Expenses (USD)
0100M200M300MR&DSG&ACapex201720182019202020212022202320242025
KNSA Expenses (USD) by year
PeriodExpenses (USD)
2025294.69M
2024279.55M
2023202.23M
2022160.41M
2021202.69M
2020157.65M
2019173.17M
2018113.45M
201765.47M
Cash & Debt (USD)
0200M400M600MCashShort Term Debt201720182019202020212022202320242025
KNSA Cash & Debt (USD) by year
PeriodCash & Debt (USD)
2025414.07M
2024243.63M
2023206.37M
2022190.61M
2021182.2M
2020323.48M
2019233.38M
2018307.3M
201745.55M
Debt ratios
-7.5-5-2.502.5202020212022202320242025
KNSA Debt ratios by year
PeriodDebt ratios
2025-6.98
20241.26
20230.63
20220.4
20210.3
20200.64
Margins
0%20%40%60%80%20212022202320242025
KNSA Margins by year
PeriodMargins
202554.63%
202455.21%
202365.46%
202277.24%
202168.67%
Return on Capital
-100%-50%0%50%100%201720182019202020212022202320242025
KNSA Return on Capital by year
PeriodReturn on Capital
202510.4%
2024-9.85%
20233.21%
202246.29%
2021-85.35%
2020-51.74%
2019-71.81%
2018-36.96%
201772.32%
Shares Outstanding
020M40M60M80M201720182019202020212022202320242025
KNSA Shares Outstanding by year
PeriodShares Outstanding
202574.2M
202472.32M
202370.37M
202269.61M
202168.97M
202068.06M
201954.89M
201848.46M
201732.47M
Book Value Per Share (USD)
-50510201720182019202020212022202320242025
KNSA Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20257.65
20246.06
20236.24
20225.69
20212.68
20204.58
20194.11
20185.76
2017-2.76
Total Assets (USD)
0200M400M600M800M201720182019202020212022202320242025
KNSA Total Assets (USD) by year
PeriodTotal Assets (USD)
2025763.63M
2024580.55M
2023526.32M
2022459.67M
2021232.8M
2020349.46M
2019254.53M
2018321.96M
201747.49M
Employee Count
010020030040020182019202020212022202320242025
KNSA Employee Count by year
PeriodEmployee Count
2025366
2024315
2023297
2022220
2021215
2020168
2019137
2018111
PE Ratio
0200400600med 77.32Aug 23Mar 24Jul 24Oct 25Feb 26May 26Sep 26
KNSA PE Ratio by year
PeriodPE Ratio
Sep 2673.36
Sep 2674.93
Aug 2675.1
Aug 2676.01
Aug 2673.82
Aug 2673.16
Jul 2671.5
Jul 2665.81
Jul 2666.98
Jul 2666.44
Jul 2667.58
Jun 2662
Jun 2657.72
Jun 2654.35
Jun 2650.71
May 2650.67
May 2655.76
May 2659.19
May 2661.37
May 2657.89
Apr 2653.81
Apr 2656.46
Apr 2659.2
Apr 2661.39
Mar 2657.53
Mar 2657.95
Mar 2657.57
Mar 2658.05
Feb 2655.95
Feb 2697.89
Feb 2692.98
Feb 2688.3
Jan 2690
Jan 2686.48
Jan 2680.76
Jan 2687.44
Jan 2686.09
Dec 2586.07
Dec 2588.51
Dec 2585.23
Dec 2585.39
Nov 2587.13
Nov 2585.21
Nov 2582.63
Nov 2578.63
Oct 2575.84
Oct 25596.86
Oct 25592.42
Oct 25580.92
Oct 25590.12
Sep 25559.45
Sep 25543.05
Sep 25568.81
Sep 25547.5
Aug 25513.46
Aug 25517.45
Aug 25511.77
Aug 25492.92
Aug 25490.31
Jul 24173.36
Jul 24173.19
Jul 24158.09
Jun 24152.45
Jun 24151.96
Jun 24153.27
Jun 24155.64
May 24155.23
May 24155.56
May 24161.44
May 24159.48
May 24163.97
Apr 24146
Apr 2484.49
Apr 2486.39
Apr 2489.44
Mar 2498.58
Mar 2499.78
Mar 2499.88
Mar 24103.98
Mar 24108.63
Oct 234.61
Oct 234.71
Oct 234.93
Oct 234.98
Sep 235.25
Sep 235.03
Sep 235.18
Sep 235.22
Sep 235.37
Aug 235.28
Aug 235.09
Aug 235.17
Aug 235.53
Jul 236.73
Jul 235.54
Jul 235.16
Jul 234.84
Jun 235
Jun 235.49
Jun 235.53
Free Cash Flow Yield
0%1%2%3%4%5%med 2.69%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
KNSA Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 263.09%
Sep 263.03%
Aug 263.02%
Aug 262.99%
Aug 263.08%
Aug 263.1%
Jul 263.17%
Jul 263.42%
Jul 263.36%
Jul 263.38%
Jul 263.33%
Jun 263.63%
Jun 263.89%
Jun 264.14%
Jun 264.43%
May 264.44%
May 264.03%
May 263.8%
May 263.66%
May 263.88%
Apr 264.3%
Apr 264.09%
Apr 263.91%
Apr 263.77%
Mar 264.02%
Mar 263.99%
Mar 264.02%
Mar 263.98%
Feb 264.13%
Feb 262.89%
Feb 263.05%
Feb 263.21%
Jan 263.15%
Jan 263.28%
Jan 263.51%
Jan 263.24%
Jan 263.29%
Dec 253.29%
Dec 253.2%
Dec 253.32%
Dec 253.32%
Nov 253.25%
Nov 253.32%
Nov 253.43%
Nov 253.6%
Oct 253.73%
Oct 252.33%
Oct 252.34%
Oct 252.39%
Oct 252.35%
Sep 252.48%
Sep 252.56%
Sep 252.44%
Sep 252.54%
Aug 252.7%
Aug 252.68%
Aug 252.71%
Aug 252.82%
Aug 252.83%
Jul 252.29%
Jul 252.07%
Jul 252.14%
Jul 252.16%
Jun 252.15%
Jun 252.12%
Jun 252.13%
Jun 251.99%
May 252.2%
May 252.24%
May 252.29%
May 252.31%
May 252.18%
Apr 251.64%
Apr 251.74%
Apr 251.82%
Apr 251.73%
Mar 251.52%
Mar 251.5%
Mar 251.55%
Mar 251.63%
Feb 251.73%
Feb 250.77%
Feb 250.78%
Feb 250.79%
Jan 250.79%
Jan 250.77%
Jan 250.84%
Jan 250.78%
Jan 250.76%
Dec 240.77%
Dec 240.75%
Dec 240.77%
Dec 240.72%
Nov 240.7%
Nov 240.73%
Nov 240.73%
Nov 240.68%
Nov 240.69%
Oct 241.56%
Oct 241.63%
Price to Sales
345678med 4.91Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
KNSA Price to Sales by year
PeriodPrice to Sales
Sep 267.04
Sep 267.19
Aug 267.2
Aug 267.29
Aug 267.08
Aug 267.02
Jul 266.86
Jul 266.38
Jul 266.49
Jul 266.44
Jul 266.55
Jun 266.01
Jun 265.59
Jun 265.27
Jun 264.91
May 264.91
May 265.4
May 265.73
May 265.95
May 265.61
Apr 264.69
Apr 264.92
Apr 265.16
Apr 265.35
Mar 265.01
Mar 265.05
Mar 265.01
Mar 265.06
Feb 264.87
Feb 265.88
Feb 265.58
Feb 265.3
Jan 265.41
Jan 265.19
Jan 264.85
Jan 265.25
Jan 265.17
Dec 255.17
Dec 255.32
Dec 255.12
Dec 255.13
Nov 255.23
Nov 255.12
Nov 254.96
Nov 254.72
Oct 254.56
Oct 255.4
Oct 255.36
Oct 255.26
Oct 255.34
Sep 255.06
Sep 254.91
Sep 255.15
Sep 254.95
Aug 254.65
Aug 254.68
Aug 254.63
Aug 254.46
Aug 254.44
Jul 253.98
Jul 254.38
Jul 254.24
Jul 254.21
Jun 254.23
Jun 254.29
Jun 254.27
Jun 254.56
May 254.13
May 254.06
May 253.96
May 253.93
May 254.17
Apr 253.65
Apr 253.45
Apr 253.3
Apr 253.48
Mar 253.95
Mar 253.99
Mar 253.86
Mar 253.68
Feb 253.47
Feb 253.74
Feb 253.69
Feb 253.64
Jan 253.66
Jan 253.74
Jan 253.46
Jan 253.72
Jan 253.79
Dec 243.74
Dec 243.85
Dec 243.77
Dec 244.02
Nov 244.12
Nov 243.97
Nov 243.98
Nov 244.27
Nov 244.2
Oct 245.75
Oct 245.5
EV/EBITDA
050100150200med 39.37May 23Aug 23Aug 25Nov 25Feb 26Jun 26Sep 26
KNSA EV/EBITDA by year
PeriodEV/EBITDA
Sep 2648.17
Sep 2649.31
Aug 2649.43
Aug 2650.08
Aug 2648.51
Aug 2648.03
Jul 2646.84
Jul 2640.4
Jul 2641.19
Jul 2640.82
Jul 2641.6
Jun 2637.81
Jun 2634.9
Jun 2632.62
Jun 2630.15
May 2630.12
May 2633.57
May 2635.9
May 2637.38
May 2635.02
Apr 2630.64
Apr 2632.37
Apr 2634.16
Apr 2635.59
Mar 2633.07
Mar 2633.34
Mar 2633.09
Mar 2633.4
Feb 2632.03
Feb 2663.34
Feb 2659.81
Feb 2656.46
Jan 2657.68
Jan 2655.16
Jan 2651.06
Jan 2655.85
Jan 2654.88
Dec 2554.86
Dec 2556.61
Dec 2554.26
Dec 2554.38
Nov 2555.63
Nov 2554.25
Nov 2552.4
Nov 2549.53
Oct 2547.53
Oct 25162.46
Oct 25161.11
Oct 25157.61
Oct 25160.41
Sep 25151.09
Sep 25146.1
Sep 25153.93
Sep 25147.46
Aug 25137.11
Aug 25138.32
Aug 25136.6
Aug 25130.87
Aug 25130.08
Oct 2318.96
Oct 2319.43
Oct 2320.53
Oct 2320.75
Sep 2322.1
Sep 2321.02
Sep 2321.76
Sep 2321.97
Sep 2322.68
Aug 2322.22
Aug 2321.29
Aug 2321.7
Aug 2323.48
Jul 2339.03
Jul 2331.01
Jul 2328.48
Jul 2326.3
Jun 2327.4
Jun 2330.7
Jun 2330.94
Jun 2329.72
Jun 2328.67
May 2327.38
May 2325.71
May 2326.37
May 2326.47
Apr 2336.97
Apr 2341.12
Apr 2339.7
Apr 2336.78
Mar 2337.01
Mar 2339.98
Mar 2339.98
Mar 2342.63
Mar 2343.95
Price/Operating Cashflow
050100150med 36.88Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
KNSA Price/Operating Cashflow by year
PeriodPrice/Operating Cashflow
Sep 2631.94
Sep 2632.63
Aug 2632.7
Aug 2633.1
Aug 2632.14
Aug 2631.86
Jul 2631.14
Jul 2628.99
Jul 2629.5
Jul 2629.27
Jul 2629.77
Jun 2627.31
Jun 2625.42
Jun 2623.94
Jun 2622.34
May 2622.32
May 2624.56
May 2626.07
May 2627.03
May 2625.5
Apr 2623.01
Apr 2624.14
Apr 2625.32
Apr 2626.25
Mar 2624.6
Mar 2624.78
Mar 2624.62
Mar 2624.82
Feb 2623.92
Feb 2634.18
Feb 2632.47
Feb 2630.83
Jan 2631.43
Jan 2630.2
Jan 2628.2
Jan 2630.53
Jan 2630.06
Dec 2530.05
Dec 2530.91
Dec 2529.76
Dec 2529.82
Nov 2530.43
Nov 2529.75
Nov 2528.85
Nov 2527.46
Oct 2526.48
Oct 2542.7
Oct 2542.39
Oct 2541.56
Oct 2542.22
Sep 2540.03
Sep 2538.85
Sep 2540.7
Sep 2539.17
Aug 2536.74
Aug 2537.02
Aug 2536.62
Aug 2535.27
Aug 2535.08
Jul 2543.45
Jul 2547.89
Jul 2546.35
Jul 2546
Jun 2546.27
Jun 2546.93
Jun 2546.7
Jun 2549.88
May 2545.15
May 2544.37
May 2543.32
May 2542.95
May 2545.63
Apr 2560.16
Apr 2556.89
Apr 2554.36
Apr 2557.32
Mar 2565
Mar 2565.76
Mar 2563.65
Mar 2560.55
Feb 2557.09
Feb 25127.71
Feb 25125.92
Feb 25124.33
Jan 25125.03
Jan 25127.77
Jan 25118.27
Jan 25127.14
Jan 25129.56
Dec 24127.65
Dec 24131.35
Dec 24128.86
Dec 24137.22
Nov 24140.85
Nov 24135.75
Nov 24135.81
Nov 24145.83
Nov 24143.4
Oct 2463.95
Oct 2461.2
Price to Book
246810med 5.36Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
KNSA Price to Book by year
PeriodPrice to Book
Sep 269.05
Sep 269.24
Aug 269.26
Aug 269.37
Aug 269.1
Aug 269.02
Jul 268.82
Jul 267.94
Jul 268.08
Jul 268.01
Jul 268.15
Jun 267.48
Jun 266.96
Jun 266.56
Jun 266.12
May 266.11
May 266.73
May 267.14
May 267.4
May 266.98
Apr 265.59
Apr 265.87
Apr 266.15
Apr 266.38
Mar 265.98
Mar 266.02
Mar 265.98
Mar 266.03
Feb 265.82
Feb 266.57
Feb 266.24
Feb 265.92
Jan 266.04
Jan 265.8
Jan 265.42
Jan 265.87
Jan 265.78
Dec 255.77
Dec 255.94
Dec 255.72
Dec 255.73
Nov 255.85
Nov 255.72
Nov 255.54
Nov 255.28
Oct 255.09
Oct 255.78
Oct 255.73
Oct 255.62
Oct 255.71
Sep 255.41
Sep 255.25
Sep 255.5
Sep 255.3
Aug 254.97
Aug 255.01
Aug 254.95
Aug 254.77
Aug 254.74
Jul 254.18
Jul 254.61
Jul 254.46
Jul 254.43
Jun 254.45
Jun 254.52
Jun 254.49
Jun 254.8
May 254.34
May 254.27
May 254.17
May 254.13
May 254.39
Apr 253.52
Apr 253.33
Apr 253.19
Apr 253.36
Mar 253.81
Mar 253.85
Mar 253.73
Mar 253.55
Feb 253.35
Feb 253.29
Feb 253.24
Feb 253.2
Jan 253.22
Jan 253.29
Jan 253.04
Jan 253.27
Jan 253.33
Dec 243.28
Dec 243.38
Dec 243.32
Dec 243.53
Nov 243.62
Nov 243.49
Nov 243.49
Nov 243.75
Nov 243.69
Oct 244.48
Oct 244.29
Kiniksa Pharmaceuticals International, plc
KNSA
Stockpicker

Video analysis: KNSA

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: KNSA

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

globenewswire.com · 4 Sep 2026

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3

marketbeat.com · 14 Aug 2026

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3

Kiniksa Pharmaceuticals International NASDAQ: KNSA said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on candidate KPL-387.

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

globenewswire.com · 7 Aug 2026

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time.

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

zacks.com · 3 Aug 2026

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

zacks.com · 30 Jul 2026

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

seekingalpha.com · 28 Jul 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights

marketbeat.com · 28 Jul 2026

Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights

Kiniksa Pharmaceuticals International NASDAQ: KNSA reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited continued expansion in both new and repeat prescribers for the recurrent pericarditis treatment.

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates

zacks.com · 28 Jul 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.3 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.23 per share a year ago.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.